Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Full length recombinant p21protien.|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
IP-MS enrichment of P21 (LFQ intensity): P21 was enriched 285-fold from HCT116 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and P21 antibody (Part No. MA1-12303). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
MA1-12303 was used in western blot to study the roles CDK7 and p21 in regulating the T172 phosphorylation of CDK4 at the restriction point
|Bisteau X,Paternot S,Colleoni B,Ecker K,Coulonval K,De Groote P,Declercq W,Hengst L,Roger PP||PLoS genetics (9:null)||2013|
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
MA1-12303 was used in immunohistochemistry to study the immunohistochemical expression of p53, p21, p27, cyclin D1 and Ki67 in oral and oropharyngeal squamous cell carcinoma
|Perisanidis C,Perisanidis B,Wrba F,Brandstetter A,El Gazzar S,Papadogeorgakis N,Seemann R,Ewers R,Kyzas PA,Filipits M||Journal of oral pathology and medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (41:40)||2012|
Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
MA1-12303 was used in immunohistochemistry to study the diagnostic and prognostic value of cell cycle regulators in differentiated thyroid cancer
|Melck A,Masoudi H,Griffith OL,Rajput A,Wilkins G,Bugis S,Jones SJ,Wiseman SM||Annals of surgical oncology (14:3403)||2007|
p21CDKN1A participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1.
MA1-12303 was used in immunocytochemistry to study the role of poly(ADP-ribose) polymerase-1 in the mechanism by which p21CDKN1A participates in base excision repair
|Cazzalini O,Donà F,Savio M,Tillhon M,Maccario C,Perucca P,Stivala LA,Scovassi AI,Prosperi E||DNA repair (9:627)||2010|
CAP20; CDK-interacting protein 1; CDK-interaction protein 1; CDKN1; CDNK1A; Cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA synthesis inhibitor; MDA-6; melanoma differentiation associated protein 6; Melanoma differentiation-associated protein 6; p21; p21CIP1; SDI1; WAF1; wild-type p53-activated fragment 1
CAP20; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; P21; p21CIP1; PIC1; SDI1; WAF1